Treatment for diabetic macula edema (DME) and retinal vein occlusion (RVO) primarily involves intravitreal injections of anti-VEGF agents and/or steroids. While anti-VEGF therapy has become the standard of care, steroid use retains distinct market potential within specific patient populations. Understanding the drivers behind treatment selection is crucial for developing effective commercial strategies in this space.
By leveraging real-world patient data from Ipsos' Ophthalmology Therapy Monitor and applying CHAID segmentation analysis, specific patient clusters where HCPs demonstrate clear preferences between anti-VEGF drugs and steroids are identified. By examining demographics, disease characteristics, and severity indicators, we provide clear mapping of the decision pathways that influence prescribing behaviour.
Identify and capitalise on untapped opportunities in the retinal treatment market with Ipsos' actionable intelligence.
CHAID (Chi-squared Automatic Interaction Detector): A decision tree methodology to explore relationships between categorical variables
- Precise identification of high-potential patient segments
- How to align marketing messages with actual HCP decision drivers
- Where to optimise resource allocation for maximum market impact
- The ability to develop competitive positioning based on real-world prescribing patterns
- Insights from one consistent, robust data source
- Built on large samples of real-world patient records, ensuring analytical credibility
- Crafted by Ipsos' dedicated statistical and ophthalmology experts
Sample excerpt from report
- 20 slides
- Data collection timeframe: Q2 2024
- Data source: Ipsos Ophthalmology Therapy Monitor
- Statistical analysis methods: CHAID
- Respondent type: HCPs (n=300), patient record forms (n=1,200; DME; n=800 RVO)
- Regions shown: Aggregate of France, Germany, Italy, Spain, UK for each indication
- Consistent global data, large-scale datasets